Spain | Exports | Belgium | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2011 - 2022
| Commodity | Reporter | Partner | Trade flow | Indicator | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| 3002. Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc | Spain | Belgium | Exports | Value (US$) | 19,832,832.00 | 25,017,878.00 | 36,504,826.00 | 45,869,760.86 | 29,922,016.73 | 38,543,919.24 | 68,718,568.19 | 104,132,738.60 | 101,317,331.12 | 61,643,743.18 | 5,388,152,012.50 | 13,077,048,941.44 |
| Value Growth, YoY (%) | 239.34 | 26.14 | 45.91 | 25.65 | -34.76 | 28.81 | 78.28 | 51.53 | -2.70 | -39.15 | 8,640.79 | 142.70 |
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Spain to Belgium totalled $ 13 billion in 2022. Sales of commodity group 3002 from Spain to Belgium increased by 142% compared to 2021: exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 7.68 billion (exports of commodity group 3002 from Spain to Belgium were equal to $5.38 billion in 2021)
Exports of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Spain to Belgium accounted for 52% of the total merchandise exports in 2022 (total sales of goods from Spain to Belgium were equal to $ 25 billion in 2022). The share of commodity group 3002 grew up by 20 p.p. in overall exports from Spain to Belgium compared to 2021 (it was 31% in 2021 and cumulative exports from Spain to Belgium were equal to $ 17 billion).
Exports of commodity group 3002 accounted for 98% of total sales of commodity group "" from Spain to Belgium in 2022 (cumulative exports of commodity group from Spain to Belgium were equal to $13.2 billion in 2022). The share of exports of commodity group 3002 in sales of commodity group from Spain to Belgium went up by 1.95 p.p. compared to 2021 (it was 96% in 2021, and exports of commodity group from Spain to Belgium were $5.58 billion).
The share of Belgium in total exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Spain was 83 percent (13 billion USD) in 2022 of 15.6 billion USD - the value of overall merchandise exports of commodity group 3002 from Spain in 2022. The share of Belgium in exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Spain grew up by 16.9 p.p. in value terms compared to 2021 (it was 66 percent in 2021, and overall exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Spain amounted to 8.08 billion USD).
